Stopping harmful PANoptosis to help people with myelodysplastic syndromes
Targeting PANoptotic pathways for Myelodysplastic Syndromes treatment
Researchers aim to block a form of inflammatory cell death called PANoptosis to try to improve blood counts and reduce disease progression in people with myelodysplastic syndromes (MDS).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Loyola University Chicago NIH-funded |
| Lab location | 1 site (Maywood, United States) |
| Project ID | NIH-11306607 on NIH RePORTER |
What this research studies
This research looks at bone marrow samples from people with MDS to understand how PANoptosis (a combined form of programmed cell death) contributes to low blood counts and disease progression. The team will study patient-derived cells and use laboratory and animal models to test genetic and drug approaches that reduce PANoptosis in mutant hematopoietic stem and progenitor cells. They will measure whether blocking PANoptosis improves healthy blood cell production and reduces the survival or expansion of the disease-causing clones. Findings will guide development of new therapies aimed at preventing cytopenias and transformation to acute myeloid leukemia.
Who could benefit from this research
Good fit: People diagnosed with myelodysplastic syndromes, especially those with spliceosome mutations such as SF3B1 or with persistent cytopenias, would be the most relevant candidates for related clinical work.
Not a fit: Patients whose bone marrow disease is driven by unrelated mechanisms or who are too frail for future therapies may not benefit from approaches targeting PANoptosis.
Why it matters
Potential benefit: If successful, this work could lead to treatments that raise blood counts, lower transfusion needs, and reduce the risk of progression to acute leukemia for people with MDS.
How similar studies have performed: Targeting PANoptosis is a relatively new idea with limited direct human data, though early clinical work on spliceosome inhibitors and related cell-death pathway approaches has shown promising signals.
Where this research is happening
Maywood, United States
- Loyola University Chicago — Maywood, United States (Active)
Researchers
- Principal investigator: Zhang, Jiwang — Loyola University Chicago
- Study coordinator: Zhang, Jiwang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.